These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 32387043)

  • 21. Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation.
    Dilokthornsakul P; Patidar M; Campbell JD
    Value Health; 2017 Dec; 20(10):1329-1335. PubMed ID: 29241892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].
    Desch M
    Med Monatsschr Pharm; 2016 Jan; 39(1):42-4. PubMed ID: 26975180
    [No Abstract]   [Full Text] [Related]  

  • 23. A Case Report of Pregnancy During Use of Targeted Therapeutics for Cystic Fibrosis.
    Ladores S; Kazmerski TM; Rowe SM
    J Obstet Gynecol Neonatal Nurs; 2017; 46(1):72-77. PubMed ID: 27875677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
    Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
    Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis.
    Hammond JA; Connett GJ
    Paediatr Respir Rev; 2018 Jun; 27():16-17. PubMed ID: 29914743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor.
    Mainz JG; Michl RK; Beiersdorf N; Lorenz M; Schneider U; Groten T; Jaudszus A
    Klin Padiatr; 2019 Sep; 231(5):271-273. PubMed ID: 31408905
    [No Abstract]   [Full Text] [Related]  

  • 27. Metabolomic responses to lumacaftor/ivacaftor in cystic fibrosis.
    Kopp BT; McCulloch S; Shrestha CL; Zhang S; Sarzynski L; Woodley FW; Hayes D
    Pediatr Pulmonol; 2018 May; 53(5):583-591. PubMed ID: 29461009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator on high-dose ibuprofen therapy in pediatric cystic fibrosis patients.
    Bruch BA; Singh SB; Ramsey LJ; Starner TD
    Pediatr Pulmonol; 2018 Aug; 53(8):1035-1039. PubMed ID: 29717552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor.
    Schneider EK
    Drug Metab Lett; 2018; 12(1):71-74. PubMed ID: 29595119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.
    Schneider EK; Azad MA; Han ML; Tony Zhou Q; Wang J; Huang JX; Cooper MA; Doi Y; Baker MA; Bergen PJ; Muller MT; Li J; Velkov T
    ACS Infect Dis; 2016 Jul; 2(7):478-88. PubMed ID: 27626100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States.
    Sharma D; Xing S; Hung YT; Caskey RN; Dowell ML; Touchette DR
    Orphanet J Rare Dis; 2018 Sep; 13(1):172. PubMed ID: 30268148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination Therapy with Lumacaftor-Ivacaftor in Cystic Fibrosis. Keeping It Real.
    Sala MA; Jain M
    Am J Respir Crit Care Med; 2020 Jan; 201(2):133-134. PubMed ID: 31639314
    [No Abstract]   [Full Text] [Related]  

  • 33. Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients.
    Schneider EK; Reyes-Ortega F; Li J; Velkov T
    J Vis Exp; 2017 Oct; (128):. PubMed ID: 29155707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.
    Casciaro R; Costa S; Dang P; Majo F; Ros M
    Clin Respir J; 2018 Apr; 12(4):1767-1768. PubMed ID: 28759146
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of Lumacaftor/Ivacaftor in a Pediatric Cohort Homozygous for F508del-CFTR.
    Egan ME
    Am J Respir Crit Care Med; 2017 Apr; 195(7):849-850. PubMed ID: 28362199
    [No Abstract]   [Full Text] [Related]  

  • 36. Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa.
    Barnaby R; Koeppen K; Nymon A; Hampton TH; Berwin B; Ashare A; Stanton BA
    Am J Physiol Lung Cell Mol Physiol; 2018 Mar; 314(3):L432-L438. PubMed ID: 29146575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract]   [Full Text] [Related]  

  • 38. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
    Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
    Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Negotiations between the NHS and Vertex on access to lumacaftor and ivacaftor become protracted.
    Burki TK
    Lancet Respir Med; 2019 Sep; 7(9):739-740. PubMed ID: 31353281
    [No Abstract]   [Full Text] [Related]  

  • 40. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
    Brewington JJ; McPhail GL; Clancy JP
    Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.